MHC Class I Antigens In Malignant Cells

Immune Escape And Response To Immunotherapy

  • Natalia Aptsiauri
  • Angel Miguel Garcia-Lora
  • Teresa Cabrera

Part of the SpringerBriefs in Cancer Research book series (BRIEFSCANCER, volume 6)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
    Pages 1-11
  3. Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
    Pages 13-30
  4. Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
    Pages 51-51

About this book

Introduction

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​  

Keywords

Immunotherapy MHC class I cancer immune escape metastasis tumor rejection

Authors and affiliations

  • Natalia Aptsiauri
    • 1
  • Angel Miguel Garcia-Lora
    • 2
  • Teresa Cabrera
    • 3
  1. 1., Servicio de Análisis ClínicosHosp. Universitario Virgen de las NievesGranadaSpain
  2. 2.Hosp. Universitario Virgen de las NievesGranadaSpain
  3. 3., Servicio de Análisis ClínicosHosp. Universitario Virgen de las NievesGranadaSpain

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4614-6543-0
  • Copyright Information Maria Teresa Cabrera Castillo 2013
  • Publisher Name Springer, New York, NY
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-1-4614-6542-3
  • Online ISBN 978-1-4614-6543-0
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma